Intraventricular Hemorrhage of Prematurity Clinical Trial
Official title:
Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study
The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the effect of intravenously administered recombinant human erythropoietin (Epo) as compared to placebo in preterm infants with brain damage on neurological development until five years od age.
Worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation,
which is more than 2 months before expected date of delivery. If these smallest infants
suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or
parenchymal infarction, they are at high risk for learning disabilities, mental retardation,
and cerebral palsy in later life.
Intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm
infants, mostly in the very smallest and within the first few days after birth, and can be
recorded by cranial ultrasound. Except for shunt insertion to divert cerebrospinal fluid in
infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is
no treatment for established intracerebral bleeding, and no medical therapies exist to
ameliorate the neurodevelopmental sequelae.
Apart from stimulating production of red blood cells in the bone marrow, recombinant human
erythropoietin (Epo) has been shown to exert neuroprotective action in a variety of animal
models and in clinical studies. Epo administration has been found to be beneficial and safe
in randomized controlled trials (RCT) involving adult and infant patients.
Observational data suggest that Epo administered to very preterm infants in order to prevent
from anemia improves long-term cognitive outcomes until school-age especially in those
infants who had suffered intracerebral bleeding. These data, however, are observational and
therefore do not allow for any firm conclusions or recommendations. The hypothesis generated
by these data calls for confirmation or refutation by an RCT designed to address this
question.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05844709 -
Effectiveness of Nursing Care Bundle for the Prevention of Intraventricular Hemorrhage in Preterm Infants
|
||
Completed |
NCT02147769 -
Cerebral Oxygenation and Autoregulation in Preterm Infants
|
||
Withdrawn |
NCT03390530 -
Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage
|
Phase 3 | |
Terminated |
NCT01482559 -
Management of Hypotension In the Preterm Infant
|
Phase 3 | |
Recruiting |
NCT06280872 -
Physiologically Based Cord Clamping To Improve Neonatal Outcomes In Moderate And Late Preterm Newborns
|
N/A | |
Terminated |
NCT03543046 -
Tortle Midliner and Intraventricular Hemorrhage
|
N/A | |
Recruiting |
NCT05617833 -
Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
|
Phase 1 |